

Characteristics	No liver involvement at onset	Liver metastasis at onset	p value
Sex			
Male	133 (67.9%)	33 (82.5%)	0.08
Female	66 (32.1%)	7 (17.5%)	
T			0.4
Tx	11 (5.6%)	0 (0%)	
T1	30 (15.3%)	5 (12.5%)	
T2	64 (32.7%)	10 (25%)	
T3	28 (14.3%)	7 (17.5%)	
T4	63 (32.1%)	18 (45%)	
N			0.3
Nx	4 (2%)		
N0	33 (16.8%)	6 (15%)	
N1	10 (5.1%)	3 (7.5%)	
N2	81 (41.3%)	11 (27.5%)	
N3	68 (34.7%)	20 (50%)	
M1	196	40	-
Bone metastases	89 (45.4%)	27 (67.5%)	0.01
Bone metastases at onset	69 (35.2%)	25 (62.5%)	0.01
Skin metastases	13 (6.6%)	4 (10%)	0.5
Skin metastases at onset	7 (3.6%)	3 (7.5%)	0.3
Adrenal metastases	55 (28.1%)	12 (30%)	0.8
Adrenal metastases at onset	33 (16.8%)	11 (27.5%)	0.1
Brain metastases	88 (44.9%)	13 (32.5%)	0.1
Brain metastases at onset	66 (33.7%)	9 (22.5%)	0.2
Smoker			0.07
Non smoker	46 (23.5%)	10 (25%)	
Ex smoker	98 (50%)	15 (37.5%)	
Smoker	50 (25.5%)	14 (35%)	
EGFR			0.06
Wild type	125 (63.8%)	19 (47.5%)	
Mutate	26 (13.3%)	4 (10%)	
Unknown	45 (23%)	17 (42.5%)	
KRAS			0.4
Wild type	71 (36.2%)	11 (27.5%)	
Mutated	19 (9.7%)	3 (7.5%)	
Unknown	106 (54.1%)	26 (65%)	
Histology			0.2
Adenocarcinoma	145 (74%)	23 (57.5%)	
Squamous cell	22 (11.2%)	7 (17.5%)	
Adenosquamous	2 (1%)	0 (0%)	
Giant cell	17 (8.7%)	7 (17.5%)	
Undifferentiated	10 (5.1%)	3 (7.5%)	
Median ECOG (range)	1 (0-2)	1 (0-2)	0.6
Media Age (range)	65.5 (47-89)	62 (35-84)	0.1
Median Number of lines (range)	2 (1-7)	2 (1-6)	0.8